Sinus bradycardia

Jump to navigation Jump to search
Sinus bradycardia
Sinus bradycardia.
ICD-9 427.81
eMedicine emerg/ 
MeSH D001146

WikiDoc Resources for Sinus bradycardia

Articles

Most recent articles on Sinus bradycardia

Most cited articles on Sinus bradycardia

Review articles on Sinus bradycardia

Articles on Sinus bradycardia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sinus bradycardia

Images of Sinus bradycardia

Photos of Sinus bradycardia

Podcasts & MP3s on Sinus bradycardia

Videos on Sinus bradycardia

Evidence Based Medicine

Cochrane Collaboration on Sinus bradycardia

Bandolier on Sinus bradycardia

TRIP on Sinus bradycardia

Clinical Trials

Ongoing Trials on Sinus bradycardia at Clinical Trials.gov

Trial results on Sinus bradycardia

Clinical Trials on Sinus bradycardia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sinus bradycardia

NICE Guidance on Sinus bradycardia

NHS PRODIGY Guidance

FDA on Sinus bradycardia

CDC on Sinus bradycardia

Books

Books on Sinus bradycardia

News

Sinus bradycardia in the news

Be alerted to news on Sinus bradycardia

News trends on Sinus bradycardia

Commentary

Blogs on Sinus bradycardia

Definitions

Definitions of Sinus bradycardia

Patient Resources / Community

Patient resources on Sinus bradycardia

Discussion groups on Sinus bradycardia

Patient Handouts on Sinus bradycardia

Directions to Hospitals Treating Sinus bradycardia

Risk calculators and risk factors for Sinus bradycardia

Healthcare Provider Resources

Symptoms of Sinus bradycardia

Causes & Risk Factors for Sinus bradycardia

Diagnostic studies for Sinus bradycardia

Treatment of Sinus bradycardia

Continuing Medical Education (CME)

CME Programs on Sinus bradycardia

International

Sinus bradycardia en Espanol

Sinus bradycardia en Francais

Business

Sinus bradycardia in the Marketplace

Patents on Sinus bradycardia

Experimental / Informatics

List of terms related to Sinus bradycardia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Sinus bradycardia is a heart rhythm that originates from the sinus node and has a rate of under 60 beats per minute. Common causes include sick sinus syndrome and pharmacotherapy such as beta-blockers. Sinus bradycardia is not unexpected in highly trained athletes. It only requires treatment if the patient is symptomatic.

Pathosphysiology

This rhythm may be caused by one of the following:

Differential Diagnosis of Causes of Sinus Bradycardia

In alphabetical order. [1] [2]

Diagnosis

Symptoms

The decreased heart rate can cause a decreased cardiac output resulting in symptoms such as lightheadedness, dizziness, hypotension, vertigo, and syncope.

Sinus bradycardia may lead to no symptoms in a young athlete.

Signs

There may be a wide pulse pressure. If cardiac output is reduced, there may be signs of end organ hypoperfusion.

Laboratory Studies

TFTs should be checked Check electrolytes, Ca, Mg Hypoglycemia should be excluded Consider a toxicologic screen

ECG Characteristics

  • Rate: Less than 60.
  • Rhythm: Regular.
  • P waves: Upright, consistent, and normal in morphology and duration.
  • PR Interval: Between 0.12-0.20 seconds in duration.
  • QRS complex: Less than 0.12 seconds in width, and consistent in morphology.
  • Early repolarization is accentuated in the setting of sinus bradycardia

EKG Examples

Treatment

Acute Management

If a patient is symptomatic, intravenous access should be established. Atropine can be administered down an endotracheal tube or can be administered intravenously. The dose is 0.5-1 mg IV or ET q 3-5 min up to 3 mg total (0.04 mg/kg). The pediatric dosing is 0.02 mg/kg/dose IV, minimum of 0.1 mg. Isoproteronol (Isoprel) has been used in the past, but carries risks. Transcutaneous pacing can be undertaken while a temporary wire is being placed. Offending or exacerbating agents such as beta-blockers, calcium channel blockers or digitalis should be discontinued and underlying causes treated. Sleep apnea is a common cause and should be treated with weight loss and BiPAP. Continuous monitoring in the hospital is recommended.

Chronic Management

Asymptomatic sinus bradycardia requires no treatment. Patients with Sick Sinus Syndrome generally require a pacemaker.

ACC/AHA/HRS Guideline Recommendations for Pacemaker Implantation

{{cquote| Recommendations for Permanent Pacing in Sinus Node Dysfunction

Class I

1. Permanent pacemaker implantation is indicated for SND with documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms.(Level of Evidence: C)

2. Permanent pacemaker implantation is indicated for symptomatic chronotropic incompetence. (Level of Evidence: C)

3. Permanent pacemaker implantation is indicated for symptomatic sinus bradycardia that results from required drug therapy for medical conditions. (Level of Evidence: C)

Class IIa

1. Permanent pacemaker implantation is reasonable for SND with heart rate less than 40 bpm when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented. (Level of Evidence:C)

2. Permanent pacemaker implantation is reasonable for syncope of unexplained origin when clinically significant abnormalities of sinus node function are discovered or provoked in electrophysiological studies. (Level of Evidence: C)

Class IIb

1. Permanent pacemaker implantation may be considered in minimally symptomatic patients with chronic heart rate less than 40 bpm while awake. (Level of Evidence: C)

Class III

1. Permanent pacemaker implantation is not indicated for SND in asymptomatic patients. (Level of Evidence:C)

2. Permanent pacemaker implantation is not indicated for SND in patients for whom the symptoms suggestive of bradycardia have been clearly documented to occur in the absence of bradycardia. (Level of Evidence:C)

3. Permanent pacemaker implantation is not indicated for SND with symptomatic bradycardia due to nonessential drug therapy. (Level of Evidence: C)

References

  1. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X

See also

Additional resources

Template:SIB sv:Sinusbradykardi


Template:WikiDoc Sources